NORTHLEAF-CAPITAL
8.1.2020 10:02:14 CET | Business Wire | Press release
Northleaf Capital Partners (Northleaf) is pleased to announce that funds managed by Northleaf have acquired a 90% stake in Douglas Terminals from Hartree Partners (UK) Limited (Hartree) and Ghent Transport & Storage NV (GTS).
Douglas Terminals is a 557,000-cubic metre liquid bulk storage terminal based in the Port of Ghent, Belgium. The facility consists of 17 high-quality tanks currently used for the storage of jet fuel, gasoil, diesel and biodiesel. Hartree and GTS started commercial operations at the terminal in 2017. GTS will retain a 10% stake and continue to operate the terminal under a management services agreement. As part of the transaction, Hartree, GTS and Northleaf have agreed to jointly develop Max Terminals, a new liquid storage terminal to be located on land adjacent to the Douglas Terminals site.
“Direct investments in high-quality bulk liquid storage assets are consistent with Northleaf’s strategy and offer our investors significant potential for stable, long-term returns,” said Roderick Gadsby, Managing Director at Northleaf. “This investment further strengthens and diversifies Northleaf’s portfolio of bulk liquid storage assets that now includes investments in the United States, United Kingdom, Belgium, Australia and New Zealand.”
“We are delighted to announce this transaction and are confident that Northleaf is the right majority owner of Douglas Terminals, given its experience in the liquid storage sector,” said Heiko Voelker, Director at Hartree. “We look forward to partnering with Northleaf on the development of Max Terminals in the future.”
“We have found our ideal long-term partner in Northleaf and are pleased that it supports Douglas Terminals’ strategy going forward,” said Yves Bienfet, Owner at GTS. “We are eager to work together with them in relation to Douglas Terminals, the development of Max Terminals and future opportunities in liquid storage.”
About Northleaf Capital Partners
Northleaf Capital Partners is an independent global private markets investment firm with more than US$13 billion in private equity, private credit and infrastructure commitments under management on behalf of public, corporate and multi-employer pension plans, endowments, foundations, financial institutions and family offices. Northleaf’s 140-person team, located in Toronto, Montreal, London, New York, Chicago, Menlo Park and Melbourne, is focused exclusively on sourcing, evaluating and managing private markets investments globally. Northleaf’s portfolio includes more than 350 active investments in 34 countries, with a focus on mid-market companies and assets. Northleaf currently manages seven global private equity funds, two specialist global private equity secondaries funds, three global private credit funds, three direct OECD-focused infrastructure funds and a series of customized investment mandates tailored to meet the specific needs of institutional investors and family offices. For more information on Northleaf, please visit www.northleafcapital.com .
About Hartree Partners (UK) Limited
Hartree Partners is a global merchant commodities firm specializing in energy, commodities and their associated industries. Formed in 1997, the firm now has over 10 offices around the world. The firm focuses on identifying value in the production, refinement, transportation and consumption of tradable commodities, and anticipating opportunities in the supply chain. Hartree Partners’ trading, investment and fund management arms are especially active in the energy and metals markets as well as the growing carbon and emissions markets.
About Ghent Transport & Storage NV
GTS is a family-owned business that specialises in the handling of bulk cargo. It operates three dedicated terminals in the Port of Ghent. It provides a wide range of port related services including bulk- and liquid storage, warehousing and freight forwarding.
Advisers
ABN AMRO acted as exclusive financial adviser to Hartree Partners and GTS, with Lydian acting as legal adviser.
Macquarie Capital acted as exclusive financial adviser to Northleaf Capital Partners, with Ashurst acting as legal adviser.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200108005241/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom